PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.06
D/E ratio 1.1-1.25x Medical - Pharmaceuticals median of 0.05. Walter Schloss would demand higher asset quality to justify above-average leverage.
-3.46
Net cash position versus Medical - Pharmaceuticals median net debt of 1.85. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
307.06
Coverage of 307.06 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.
0.83
Current ratio 50-75% of Medical - Pharmaceuticals median of 1.50. Martin Whitman would look for hidden assets or working capital optimization.
0.75%
Intangibles 50-90% of Medical - Pharmaceuticals median of 1.43%. Charlie Munger would examine if industry dynamics justify more tangible-heavy model.